CVS results this morning highlight the group’s excellent revenue growth prospects and pricing power. Following 8% like-for-like (LFL) revenue growth and 30bps of margin expansion in FY 22, the first ten weeks of this financial year are off to a ‘strong’ start. With net debt/EBITDA at just 0.4x, increasing development capex and a ‘healthy’ deal pipeline, the prospects for future organic and inorganic growth remain strong. We expect to hear more about the group’s medium-term capital allocation ambitions at the Capital Markets Day on November 8th.
You can email us with your enquiry by completing the form below.
Warning: The value of your investment may go down as well as up and you may lose some or all of the money you invest. Past performance is not a reliable guide to future performance. Investments denominated in a currency other than your base currency may be affected by changes in currency exchange rates.
Davy Select is designed for investors who are comfortable making their own investment decisions, without financial advice; this is known as “execution-only”. Execution-Only is not for everyone. You should ensure that you fully understand any investment and the associated risks before making a decision to invest. Alternatively, Davy can arrange for you to open a different type of account, where we can advise you in relation to investment decisions, or where we can manage investments on your behalf.
This website does not constitute investment advice as it does not take into account the investment objectives, knowledge and experience or financial situation of any particular person or persons. Prospective investors are advised to make their own assessment of the information contained herein and obtain professional advice suitable to their own individual circumstances.
J & E Davy Unlimited Company, trading as Davy and Davy Select, is regulated by the Central Bank of Ireland.